Amyloid biomarkers in Alzheimer's disease
Aggregation of amyloid-β (Aβ) into oligomers, fibrils, and plaques is central in the molecular
pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development …
pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development …
[HTML][HTML] Imaging biomarkers in neurodegeneration: current and future practices
PNE Young, M Estarellas, E Coomans… - Alzheimer's research & …, 2020 - Springer
There is an increasing role for biological markers (biomarkers) in the understanding and
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …
diagnosis of neurodegenerative disorders. The application of imaging biomarkers …
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …
Plasma phospholipids identify antecedent memory impairment in older adults
Alzheimer's disease causes a progressive dementia that currently affects over 35 million
individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no …
individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no …
18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease
R Harada, N Okamura, S Furumoto… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Imaging of neurofibrillary pathology in the brain helps in diagnosing dementia, tracking
disease progression, and evaluating the therapeutic efficacy of antidementia drugs. The …
disease progression, and evaluating the therapeutic efficacy of antidementia drugs. The …
[HTML][HTML] Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density
C Curtis, JE Gamez, U Singh, CH Sadowsky… - JAMA …, 2015 - jamanetwork.com
Importance In vivo imaging of brain β-amyloid, a hallmark of Alzheimer disease, may assist
in the clinical assessment of suspected Alzheimer disease. Objective To determine the …
in the clinical assessment of suspected Alzheimer disease. Objective To determine the …
Determining amyloid-β positivity using 18F-AZD4694 PET imaging
Amyloid-β deposition into plaques is a pathologic hallmark of Alzheimer disease appearing
years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a …
years before the onset of symptoms. Although cerebral amyloid-β deposition occurs on a …
Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease
The clinical and pathophysiological correlates of locus coeruleus (LC) degeneration in
Alzheimer's disease (AD) could be clarified using a method to index LC integrity in vivo …
Alzheimer's disease (AD) could be clarified using a method to index LC integrity in vivo …
[HTML][HTML] Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease
Abstract Background The Centiloid scale was developed to standardise the results of beta-
amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD …
amyloid (Aβ) PET. We aimed to determine the Centiloid unit (CL) thresholds for CERAD …